Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

被引：6

作者：

Blombery, Piers ^{[1
,2
,3
]}

Anderson, Mary Ann ^{[1
,2
,3
,4
]}

Gong, Jianan ^{[1
,4
]}

Thijssen, Rachel ^{[1
,4
]}

Birkinshaw, Richard W. ^{[1
,4
]}

Thompson, Ella ^{[1
,3
]}

Teh, Charis E. ^{[1
,4
]}

Nguyen, Tamia ^{[3
]}

Xu, Zhen ^{[4
]}

Flensburg, Christoffer ^{[4
]}

Lew, Thomas ^{[4
]}

Majewski, Ian ^{[4
]}

Gray, Daniel ^{[4
]}

Westerman, David Alan ^{[1
,2
,3
]}

Tam, Constantine S. ^{[1
,2
,3
]}

Seymour, John F. ^{[1
,2
,3
]}

Czabotar, Peter E. ^{[1
,4
]}

Huang, David ^{[1
,4
]}

Roberts, Andrew W. ^{[1
,2
,3
,4
,5
]}

机构：

[1] Univ Melbourne, Melbourne, Vic, Australia

[2] Royal Melbourne Hosp, Melbourne, Vic, Australia

[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[4] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia

[5] Victorian Comprehens Canc Ctr, Melbourne, Vic, Australia

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-120761

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

LBA-7

引用

页数：4

共 50 条

[21] Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
Koji Izutsu
Kazuhito Yamamoto
Koji Kato
Takayuki Ishikawa
Noriko Fukuhara
Yasuhito Terui
Ilseung Choi
Kathryn Humphrey
Su Young Kim
Sumiko Okubo
Natsumi Ogawa
Yasuko Nishimura
Ahmed Hamed Salem
Dai Maruyama
International Journal of Hematology, 2021, 113 : 370 - 380
[22] Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
Izutsu, Koji
Yamamoto, Kazuhito
Kato, Koji
Ishikawa, Takayuki
Fukuhara, Noriko
Terui, Yasuhito
Choi, Ilseung
Humphrey, Kathryn
Kim, Su Young
Okubo, Sumiko
Ogawa, Natsumi
Nishimura, Yasuko
Salem, Ahmed Hamed
Maruyama, Dai
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (03) : 370 - 380
[23] Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax
Avsec, Damjan
Skrlj Miklavcic, Marja
Burnik, Tilen
Kanduser, Masa
Bizjak, Marusa
Podgornik, Helena
Mlinaric-Rascan, Irena
CELL DEATH & DISEASE, 2022, 13 (10)
[24] Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax
Damjan Avsec
Marja Škrlj Miklavčič
Tilen Burnik
Maša Kandušer
Maruša Bizjak
Helena Podgornik
Irena Mlinarič-Raščan
Cell Death & Disease, 13
[25] Knock-in of the BCL2 G101V Mutation in Human iPSC-Derived NK Cells Generates Venetoclax Resistance and Improves Activity Against Venetoclax Resistant AML
Bernareggi, Davide
Yun, Jiyoung
Goldenson, Benjamin
Kaufman, Dan S.
BLOOD, 2022, 140 : 7407 - 7408
[26] Copy number gain of the MCL1 gene locus (1q21) and acquisition of BCL2 mutation mediate resistance to venetoclax in multiple myeloma (MM) patients
Maity, Ranjan
Neri, Paola
Donovan, Justin
Kong, Madison
Hasan, Fajer
Boise, Lawrence
Bahlis, Nizar J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E22 - E23
[27] FOXP1 and BCL2 Show Similar Immunoenzymatic Pattern in Bone Marrow Trephines of Chronic Lymphocytic Leukemia Patients
Korac, Petra
Vintar, Marija Gilming
Ajdukovic, Radmila
Paro, Mirjana Mariana Kardum
Jaksic, Branimir
Dominis, Mara
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2009, 17 (06) : 500 - 504
[28] Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
Salem, Ahmed Hamed
Agarwal, Suresh K.
Dunbar, Martin
Enschede, Sari L. Heitner
Humerickhouse, Rod A.
Wong, Shekman L.
JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (04): : 484 - 492
[29] Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo
Soderquist, R.
Bates, D. J. P.
Danilov, A. V.
Eastman, A.
LEUKEMIA, 2013, 27 (11) : 2262 - 2264
[30] Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo
R Soderquist
D J P Bates
A V Danilov
A Eastman
Leukemia, 2013, 27 : 2262 - 2264

← 1 2 3 4 5 →